| 1 |
Boulmpou A.; Papadopoulos C.; Koufakis T.; Kotsa K.; Kouroupis D.; Dimakopoulos G.; Balaska A.; Zormpas G.; Doumas M.; Vassilikos V. |
Exploring the Role of Presepsin in the Prediction of Atrial Fibrillation Recurrence: Results from the PLACEBO Study |
2025 |
| 2 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Doumas M. |
Proton pump inhibitors and the development of diabetes and its complications: A risk hidden in the shadows? |
2021 |
| 3 |
Patoulias D.; Doumas M.; Papadopoulos C. |
Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus |
2022 |
| 4 |
Patoulias D.; Boulmpou A.; Papadopoulos C.E.; Doumas M. |
Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not? |
2021 |
| 5 |
Patoulias D.; Kassimis G.; Doumas M.; Papadopoulos C. |
Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery Disease |
2022 |
| 6 |
Alexandrou M.-E.; P. Theodorakopoulou M.; Boutou A.; Pella E.; Boulmpou A.; Papadopoulos C.E.; Zafeiridis A.; Papagianni A.; Sarafidis P. |
Cardiorespiratory fitness assessed by cardiopulmonary exercise testing between different stages of pre-dialysis chronic kidney disease: A systematic review and meta-analysis |
2021 |
| 7 |
Patoulias D.; Papadopoulos C.; Toumpourleka M.; Doumas M. |
Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation |
2021 |
| 8 |
Patoulias D.; Papadopoulos C.; Doumas M. |
“SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series” comment |
2022 |
| 9 |
Tzikas S.; Boulmpou A.; Bakogiannis C.; Evangeliou A.P.; Papadopoulos C.E.; Vassilikos V.; Zafeiropoulos S.; Hamilos M.; Noutsias M.; Tsigkas G.; Kanakakis I.; Keller T. |
A proposal for implementation of the chest pain unit model in Greece |
2021 |
| 10 |
Patoulias D.; Papadopoulos C.; Fragakis N.; Karagiannis A.; Doumas M. |
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease |
2022 |
| 11 |
Teperikidis E.; Boulmpou A.; Charalampidis P.; Tsavousoglou C.; Giannakoulas G.; Papadopoulos C.E.; Vassilikos V. |
5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations |
2022 |
| 12 |
Loutradis C.; Papadopoulos C.E.; Sachpekidis V.; Ekart R.; Krunic B.; Papadopoulou D.; Papagianni A.; Mallamaci F.; Zoccali C.; Sarafidis P.A. |
Lung ultrasound-guided dry-weight reduction and echocardiographic changes in clinically euvolemic hypertensive hemodialysis patients: 12-month results of a randomized controlled trial |
2022 |
| 13 |
Sotiriadou M.; Papadopoulos C.E.; Antoniadis A.P.; Roumelis P.; Vergopoulos S.; Konstantinidis P.; Pagourelias E.D.; Tzikas S.; Fragakis N.; Vassilikos V. |
The impact of atrial mechanical function on age-dependent presentation of neurocardiogenic syncope |
2021 |
| 14 |
Pella E.; Boulmpou A.; Boutou A.; Theodorakopoulou M.P.; Haddad N.; Karpetas A.; Giamalis P.; Papagianni A.; Papadopoulos C.E.; Vassilikos V.; Sarafidis P. |
Different Interdialytic Intervals and Cardiorespiratory Fitness in Patients Undergoing Hemodialysis |
2024 |
| 15 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction”;” does it deserve our attention? |
2021 |
| 16 |
Velidakis N.; Stachteas P.; Gkougkoudi E.; Papadopoulos C.; Kadoglou N.P.E. |
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease&”;#x2014;”A Narrative Clinical Review |
2024 |
| 17 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Doumas M. |
Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetes |
2022 |
| 18 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure |
2022 |
| 19 |
Patoulias D.; Papadopoulos C.; Siskos F.; Doumas M. |
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: Foe or friend?”;” [Daño renal agudo con cotransportador de sodio-glucosa-2 inhibidores en el resultado cardiovascular y renal ensayos: enemigo o amigo?] |
2023 |
| 20 |
Koufakis T.; Popovic D.S.; Papadopoulos C.; Giouleme O.; Doumas M. |
Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time! |
2024 |
| 21 |
Potoupni V.; Samaras A.; Papadopoulos C.; Boulmpou A.; Moysiadis T.; Zormpas G.; Tzikas A.; Fragakis N.; Giannakoulas G.; Vassilikos V. |
Machine-Learning-Driven Phenotyping in Heart Failure with Preserved Ejection Fraction: Current Approaches and Future Directions |
2025 |
| 22 |
Patoulias D.; Papadopoulos C.; Stavropoulos K.; Imprialos K.; Boulmpou A.; Doumas M. |
A significant dilemma in the treatment of heart failure patients with sacubitril/valsartan or sodium-glucose co-transporter 2 inhibitors: Whether to add mineralocorticoid receptor antagonists”;” [Um importante dilema no tratamento da insuficiência cardíaca com sacubitril/valsartan ou com inibidores do cotransportador de glicose e sódio 2: adicionar ou não antagonistas dos recetores dos mineralocorticoides?] |
2022 |
| 23 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Endothelial dysfunction and COVID-19: What’s the true impact on surrogate outcomes? |
2022 |
| 24 |
Voultsos P.; Bazmpani M.-A.; Papanastasiou C.A.; Papadopoulos C.E.; Efthimiadis G.; Karvounis H.; Kalogeropoulos A.P.; Karamitsos T.D. |
Magnesium Disorders and Prognosis in Heart Failure: A Systematic Review |
2022 |
| 25 |
Zormpas G.; Zioutas D.; Mitsiadis S.; Boulmpou A.; Boulmpos C.; Vassilikos V.; Papadopoulos C. |
The “Mushroom Sign”: An Interesting Case Report of Extreme Stent Malapposition |
2025 |
| 26 |
Kassimis G.; Ziakas A.; Didagelos M.; Theodoropoulos K.C.; Patoulias D.; Voultsos P.; Papadopoulos C.; Rocchiccioli P.; Karamasis G.V.; Alexopoulos D.; Sianos G. |
Shockwave Coronary Intravascular Lithotripsy System for Heavily Calcified De Novo Lesions and the Need for a Cost-Effectiveness Analysis |
2022 |
| 27 |
Tsarouchas A.; Bakogiannis C.; Mouselimis D.; Papadopoulos C.E.; Theofillogiannakos E.K.; Pagourelias E.D.; Kelemanis I.; Boulmpou A.; Antoniadis A.P.; Fragakis N.; Efthimiadis G.; Karamitsos T.D.; Vassilikos V.P. |
Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency |
2025 |
| 28 |
Boulmpou A.; Moysiadis T.; Zormpas G.; Teperikidis E.; Tsioni K.; Toumpourleka M.; Zidrou M.; Giannakoulas G.; Vassilikos V.; Papadopoulos C. |
Integrated Diagnostics for Atrial Fibrillation Recurrence: Exploratory Results from the PLACEBO Trial |
2025 |
| 29 |
Patoulias D.; Papadopoulos C.; Karagiannis A.; Doumas M. |
“Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium−glucose cotransporter 2 inhibitor? Or maybe both?” |
2022 |
| 30 |
Rallidis L.S.; Papathanasiou K.A.; Tsamoulis D.; Bouratzis V.; Leventis I.; Kalantzis C.; Malkots B.; Kalogeras P.; Tasoulas D.; Delakis I.; Lykoudis A.; Daios S.; Potoupni V.; Zervakis S.; Theofilatos A.; Kotrotsios G.; Kostakou P.M.; Kostopoulos K.; Gounopoulos P.; Mplani V.; Zacharis E.; Barmpatzas N.; Kotsakis A.; Papadopoulos C.; Trikas A.; Ziakas A.; Skoularigis I.; Naka K.K.; Tziakas D.; Panagiotakos D.; Vlachopoulos C. |
Newly detected diabetes mellitus patients with acute coronary syndrome have an adverse cardiometabolic profile similar to patients with prior diabetes and a more extensive ischemic myocardial insult |
2024 |
| 31 |
Fragakis N.; Antoniadis A.P.; Sotiriadou M.; Virgiliou C.; Ballauri I.; Gika H.G.; Bougiouklis D.; Gerou S.; Lazaridis C.; Vergopoulos S.; Bakogiannis C.; Giannopoulos G.; Theodoridis G.A.; Papadopoulos C.E.; Karamitsos T.D.; Vassilikos V. |
Syncope without prodromes is associated with excessive plasma release of adenosine at the time of syncope during head-up tilt table test |
2022 |
| 32 |
Patoulias D.; Papadopoulos C.; Boulmpou A.; Stavropoulos K.; Doumas M. |
Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials”;” are there any drug differences? |
2022 |
| 33 |
Pella E.; Theodorakopoulou M.P.; Boutou A.K.; Alexandrou M.-E.; Bakaloudi D.-R.; Sarridou D.; Boulmpou A.; Papadopoulos C.; Papagianni A.; Sarafidis P. |
Cardiopulmonary reserve examined with cardiopulmonary exercise testing in individuals with chronic kidney disease: A systematic review and meta-analysis |
2022 |
| 34 |
Patoulias D.; Papadopoulos C.; Fragakis N.; Karagiannis A.; Doumas M. |
Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia |
2022 |
| 35 |
Patoulias D.; Boulmpou A.; Imprialos K.; Stavropoulos K.; Papadopoulos C.; Doumas M. |
Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic”;” [Metaanálisis para evaluar el riesgo de infecciones respiratorias y síndrome de distrés respiratorio del adulto con los agonistas del receptor del péptido similar al glucagón tipo 1 en los ensayos de seguridad cardiovascular: consecuencias útiles para la pandemia de COVID-19] |
2022 |
| 36 |
Alexandrou M.-E.; Sarafidis P.; P. Theodorakopoulou Μ.; Sachpekidis V.; Papadopoulos C.; Loutradis C.; Kamperidis V.; Boulmpou A.; Bakaloudi D.-R.; Faitatzidou D.; Pateinakis P.; Papagianni A. |
Cardiac geometry, function, and remodeling patterns in patients under maintenance hemodialysis and peritoneal dialysis treatment |
2022 |
| 37 |
Pella E.; Boutou A.; Boulmpou A.; Papadopoulos C.E.; Papagianni A.; Sarafidis P. |
Cardiopulmonary exercise testing in patients with end-stage kidney disease: principles, methodology and clinical applications of the optimal tool for exercise tolerance evaluation |
2022 |
| 38 |
Tzikas S.; Papadopoulos C.H.; Evangeliou A.P.; Vassilikos V. |
First implantation of the pulsatile left ventricular assist device iVAC2L in a heart failure patient infected with influenza type A |
2021 |
| 39 |
Boulmpou A.; Patoulias D.; Papadopoulos C.E.; Teperikidis E.; Doumas M.; Vassilikos V. |
Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias |
2023 |
| 40 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Karagiannis A.; Doumas M. |
Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists |
2021 |
| 41 |
Zormpas G.; Boulmpou A.; Papadopoulos C.E.; Vassilikos V. |
“Less Metal” in a Complex Left Main Trifurcation Lesion |
2025 |
| 42 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Boulmpou A.; Karagiannis A.; Doumas M. |
Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure |
2021 |
| 43 |
Boulmpou A.; Moysiadis T.; Zormpas G.; Teperikidis E.; Vassilikos V.; Giannakoulas G.; Papadopoulos C. |
Exploring the Feasibility of Integrating Cardiopulmonary Exercise Testing, Echocardiography, and Biomarkers for Predicting Atrial Fibrillation Recurrence: Rationale, Design and Protocol for a Prospective Cohort Study (The PLACEBO Trial) |
2025 |
| 44 |
Boulmpou A.; Giannopoulos A.; Papadopoulos C.; Giannopoulos G.; Papagiannis I.; Zormpas G.; Keivanidou A.; Fidani L.; Vassilikos V. |
The Uncommon Phenomenon of Short QT Syndrome: A Scoping Review of the Literature |
2025 |
| 45 |
Boulmpou A.; Boutou A.K.; Pella E.; Sarafidis P.; Papadopoulos C.E.; Vassilikos V. |
Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction: Technique Principles, Current Evidence, and Future Perspectives |
2023 |
| 46 |
Karkos C.D.; Papadopoulos C.E. |
A Large Floating Thrombus in the Ascending Aorta: to Treat or not to Treat? |
2021 |
| 47 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Doumas M. |
Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the “miraculous” sodium-glucose co-transporter-2 inhibitors? |
2021 |
| 48 |
Gkantaifi A.; Papadopoulos C.; Toumpourleka M.; Marketou M.; Mauri D.; Giakoumettis G.; Mavroudis D.; Tolia M. |
A Prospective Study on the Role of Strain Echocardiography in Detecting Early Radiation-induced Cardiotoxicity in Left-sided Breast Cancer Patients |
2025 |
| 49 |
Teperikidis L.; Boulmpou A.; Papadopoulos C.; Biondi-Zoccai G. |
Using ChatGPT to perform a systematic review: a tutorial |
2024 |
| 50 |
Mouselimis D.; Tsarouchas A.; Vassilikos V.P.; Mitsas A.C.; Lazaridis C.; Androulakis E.; Briasoulis A.; Kampaktsis P.; Papadopoulos C.E.; Bakogiannis C. |
The role of patient-oriented mHealth interventions in improving heart failure outcomes: A systematic review of the literature |
2024 |
| 51 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations |
2022 |
| 52 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?”;” [Crisis hiperglucémicas agudas con inhibidores del cotransportador de sodio y glucosa 2 en los ensayos de resultados cardiovasculares y renales: ¿un temor anticipado?] |
2022 |
| 53 |
Patoulias D.; Papadopoulos C.; Karagiannis A.; Doumas M. |
Colchicine for the prevention of COVID-19 “hard” outcomes: All that glitters is not gold |
2022 |
| 54 |
Loutradis C.; Sarafidis P.A.; Ekart R.; Tsouchnikas I.; Papadopoulos C.; Kamperidis V.; Alexandrou M.E.; Ferro C.J.; Papagianni A.; London G.; Mallamaci F.; Zoccali C. |
Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial |
2021 |
| 55 |
Tsarouchas A.; Vassilikos V.P.; Mouselimis D.; Papadopoulos C.E.; Tachmatzidis D.; Vassilikou A.; Bakogiannis C. |
Iron Deficiency in Heart Failure: Cellular Mechanisms and Therapeutic Implications |
2025 |
| 56 |
Patoulias D.; Papadopoulos C.; Karagiannis A.; Doumas M. |
Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists |
2022 |
| 57 |
Patoulias D.; Papadopoulos C.; Zografou I.; Katsimardou A.; Karagiannis A.; Doumas M. |
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study |
2022 |
| 58 |
Patoulias D.; Boulmpou A.; Doumas M.; Papadopoulos C.E. |
Another brick in the wall of cardioprotection? A meta-analysis addressing the effect of sodium-glucose co-transporter 2 inhibitors on left ventricular mass assessed by cardiovascular magnetic resonance in patients with heart failure with reduced ejection fraction |
2022 |
| 59 |
Bakogiannis C.; Mouselimis D.; Tsarouchas A.; Papadopoulos C.E.; Theofillogiannakos E.K.; Lechat E.; Antoniadis A.P.; Pagourelias E.D.; Kelemanis I.; Tzikas S.; Fragakis N.; Efthimiadis G.K.; Karamitsos T.D.; Doumas M.; Vassilikos V.P. |
Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE-HF trial |
2023 |
| 60 |
Boulmpou A.; Theodorakopoulou M.P.; Boutou A.K.; Alexandrou M.-E.; Papadopoulos C.E.; Bakaloudi D.R.; Pella E.; Sarafidis P.; Vassilikos V. |
Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: a systematic review and meta-analysis |
2022 |
| 61 |
Patoulias D.; Papadopoulos C.; Imprialos K.; Stavropoulos K.; Doumas M. |
Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction |
2022 |
| 62 |
Pella E.; Boutou A.; Boulmpou A.; Theodorakopoulou M.P.; Karagiannidis A.G.; Haddad N.; Iatridi F.; Tsouchnikas I.; Papadopoulos C.E.; Vassilikos V.; Sarafidis P.A. |
Effect of heart failure and atrial fibrillation on cardiorespiratory fitness in hemodialysis patients |
2025 |
| 63 |
Patoulias D.; Doumas M.; Papadopoulos C.; Karagiannis A. |
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials |
2021 |
| 64 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Fragakis N.; Doumas M. |
Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity |
2022 |
| 65 |
Patoulias D.; Papadopoulos C.; Boulmpou A.; Doumas M. |
Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic |
2021 |
| 66 |
Toumpourleka M.; Siokas V.; Papadopoulos C.; Mitselou A.; Kovatsi L.; Sidiropoulou M.S.; Triantafyllou K.; Vassilikos V. |
Fatal Left Ventricular Free Wall Rupture Complicating Acute Myopericarditis |
2024 |
| 67 |
Boulmpou A.; Teperikidis E.; Papadopoulos C.; Patoulias D.I.; Charalampidis P.; Mouselimis D.; Tsarouchas A.; Boutou A.; Giannakoulas G.; Vassilikos V. |
The role of cardiopulmonary exercise testing in risk stratification and prognosis of atrial fibrillation: a scoping review of the literature |
2023 |
| 68 |
Patoulias D.I.; Boulmpou A.; Teperikidis E.; Katsimardou A.; Siskos F.; Doumas M.; Papadopoulos C.E.; Vassilikos V. |
Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials |
2021 |
| 69 |
Tsimpiris V.; Kousourna G.; Boulmpou A.; Petridou M.; Tsavousoglou C.; Kotzadamis D.; Papadopoulos C.; Ntelios D.; Moysiadis T.; Vassilikos V.; Pagourelias E. |
Mitral Annular Disjunction: Epidemiology, Diagnostic Methods, Prognosis, and Novel Implications |
2025 |
| 70 |
Theodorakopoulou M.P.; Minopoulou I.; Sarafidis P.; Kamperidis V.; Papadopoulos C.; Dimitroulas T.; Boutou A.K. |
Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis |
2021 |
| 71 |
Patoulias D.; Katsimardou A.; Fragakis N.; Papadopoulos C.; Doumas M. |
Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials |
2023 |
| 72 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19 |
2022 |
| 73 |
Patoulias D.; Toumpourleka M.; Katsimardou A.; Zografou I.; Stavropoulos K.; Imprialos K.; Karagiannis A.; Doumas M.; Papadopoulos C. |
Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study |
2022 |
| 74 |
Stachteas P.; Karakasis P.; Karagiannidis E.; Patoulias D.; Athanasiadou P.; Nasoufidou A.; Papadopoulos C.; Kassimis G.; Fragakis N. |
Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation |
2024 |
| 75 |
Stachteas P.; Nasoufidou A.; Karagiannidis E.; Patoulias D.; Karakasis P.; Alexiou S.; Samaras A.; Zormpas G.; Stavropoulos G.; Tsalikakis D.; Kassimis G.; Papadopoulos C.; Fragakis N. |
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review |
2024 |
| 76 |
Patoulias D.; Papadopoulos C.; Karagiannis A.; Doumas M. |
Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction”;” [Efectos renales de los inhibidores del cotransportador de sodio-glucosa-2 en pacientes con insuficiencia cardíaca con fracción de eyección reducida o preservada] |
2024 |
| 77 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Fragakis N.; Vassilikos V.; Karagiannis A.; Doumas M. |
Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials |
2022 |
| 78 |
Patoulias D.; Doumas M.; Kassimis G.; Fragakis N.; Papadopoulos C. |
Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure |
2022 |
| 79 |
Doumas M.; Patoulias D.; Papadopoulos C. |
Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium–glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article ‘Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure’ |
2022 |
| 80 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Sodium-glucose cotransporter 2 inhibitors and heart failure decompensation: Considerations on body composition and skeletal mass |
2021 |
| 81 |
Kouroupis D.; Zografou I.; Doukelis P.; Patoulias D.; Popovic D.S.; Karakasis P.; Pyrpasopoulou A.; Stavropoulos K.; Papadopoulos C.; Giouleme O.; Kotsa K.; Doumas M.; Koufakis T. |
Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders |
2025 |
| 82 |
Koutsampasopoulos K.; Vogiatzis I.; Ziakas A.; Papadopoulos C.; Loutradis C.; Imprialos K.P.; Stavropoulos K.; Vasilikos V.; Athyros V.G.; Karagiannis A.; Doumas M.; Papademetriou V. |
Right ventricular performance in patients with heart failure with mildly reduced ejection fraction: the forgotten ventricle |
2022 |
| 83 |
Patoulias D.; Papadopoulos C.; Doumas M.; Santulli G.; Frías J.P.; Landó L.F.; Brown K. |
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes |
2022 |
| 84 |
Charalampidis P.; Teperikidis E.; Boulmpou A.; Papadopoulos C.E.; Potoupni V.; Tsioni K.; Rakitzi P.; Karamitsos T.; Vassilikos V. |
Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature |
2022 |
| 85 |
Patoulias D.; Papadopoulos C.; Zografou I.; Katsimardou A.; Imprialos K.; Stavropoulos K.; Tranidou A.; Karagiannis A.; Doumas M. |
Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic |
2022 |
| 86 |
Mouselimis D.; Bakogiannis C.; Tsarouchas A.; Papadopoulos C.E.; Theofilogiannakos E.K.; Pagourelias E.D.; Antoniadis A.P.; Vassilikou A.; Balaska A.; Fragakis N.; Efthimiadis G.; Karamitsos T.D.; Doumas M.; Vassilikos V.P. |
Ferric carboxymaltose reduces the burden of arrhythmic events in heart failure with reduced ejection fraction: the role of the non-invasive arrhythmic biomarkers |
2024 |
| 87 |
Patoulias D.; Papadopoulos C.; Karagiannis A.; Vassilikos V.; Doumas M. |
Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus |
2022 |
| 88 |
Patoulias D.; Papadopoulos C.; Siskos F.; Stavropoulos K.; Doumas M. |
The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis |
2021 |
| 89 |
Katsimardou A.; Patoulias D.; Zografou I.; Siskos F.; Stavropoulos K.; Imprialos K.; Tegou Z.; Boulmpou A.; Georgopoulou V.; Hatzipapa N.; Papadopoulos C.; Doumas M. |
The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes |
2023 |
| 90 |
Patoulias D.; Papadopoulos C.; Toumpourleka M.; Tranidou A.; Boulmpou A.; Doumas M. |
Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders |
2021 |
| 91 |
Patoulias D.; Michailidis T.; Papadopoulos C.; Karagiannis A.; Doumas M. |
Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus |
2022 |
| 92 |
Teperikidis E.; Boulmpou A.; Papadopoulos C. |
Prompting ChatGPT to perform an umbrella review |
2024 |
| 93 |
Patoulias D.; Doumas M.; Papadopoulos C. |
Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices |
2022 |
| 94 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Vassilikos V.; Karagiannis A.; Doumas M. |
Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus |
2022 |
| 95 |
Teperikidis E.; Boulmpou A.; Potoupni V.; Kundu S.; Singh B.; Papadopoulos C. |
Does the long-term administration of proton pump inhibitors increase the risk of adverse cardiovascular outcomes? A ChatGPT powered umbrella review |
2023 |
| 96 |
Boulmpou A.; Theodorakopoulou M.P.; Alexandrou M.-E.; Boutou A.K.; Papadopoulos C.E.; Pella E.; Sarafidis P.; Vassilikos V. |
Meta-analysis addressing the impact of cardiovascular-acting medication on peak oxygen uptake of patients with HFpEF |
2022 |
| 97 |
Patoulias D.; Papadopoulos C.; Kassimis G.; Doumas M. |
Do background ischemic heart disease and baseline left ventricular ejection fraction affect cardiovascular efficacy of SGLT-2 inhibitors in heart failure with reduced ejection fraction? |
2022 |
| 98 |
Zormpas G.; Boulmpou A.; Potoupni V.; Siskos F.; Chatzipapa N.; Fragakis N.; Doumas M.; Kassimis G.; Vassilikos V.; Papadopoulos C.E. |
Identifying the Role of Flow-Mediated Dilatation Assessment in Acute Coronary Syndromes: A Systematic Review |
2024 |
| 99 |
Patoulias D.; Papadopoulos C.; Fragakis N.; Doumas M. |
Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide |
2022 |
| 100 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Meta-Analysis Addressing the Cardiovascular Safety of Daprodustat in Patients With Chronic Kidney Disease Undergoing Dialysis or Not |
2022 |
| 101 |
Patoulias D.; Stavropoulos K.; Imprialos K.; Katsimardou A.; Kalogirou M.-S.; Koutsampasopoulos K.; Zografou I.; Papadopoulos C.; Karagiannis A.; Doumas M. |
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials |
2019 |
| 102 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors? |
2021 |
| 103 |
Sarafidis P.; Papadopoulos C.E.; Kamperidis V.; Giannakoulas G.; Doumas M. |
Cardiovascular Protection with Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved |
2021 |
| 104 |
Papademetriou V.; Stavropoulos K.; Patoulias D.; Papadopoulos C.; Georgios K.; Toumpourleka M.; Sachinidis A. |
Hypertension in pregnancy: Unanswered questions |
2021 |
| 105 |
Loutradis C.; Papadopoulos C.E.; Sarafidis P. |
Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning |
2020 |
| 106 |
Styliadis I.H.; Gouzoumas N.I.; Karvounis H.I.; Papadopoulos C.E.; Efthimiadis G.K.; Karamouzis M.; Parharidis G.E.; Louridas G.E. |
Effects of variation of atrioventricular interval on left ventricular diastolic filling dynamics and atrial natriuretic peptide levels in patients with DDD pacing for complete heart block |
2005 |
| 107 |
Tzikas S.; Triantafyllou K.; Papadopoulos C.; Vassilikos V. |
A Case of a Paracardial Osteophyte Causing Atrial Compression |
2016 |
| 108 |
Boufidou A.I.; Makedou A.D.; Adamidis D.N.; Karvounis H.I.; Gourassas J.T.; Kesidis H.T.; Makedou K.G.; Papadopoulos C.E.; Parharidis G.E.; Louridas G.E. |
Association between plasma homocysteine levels and coronary artery disease: A population-based study in northern Greece |
2004 |
| 109 |
Papadopoulos C.E.; Pitsiou G.; Karamitsos T.D.; Karvounis H.I.; Kontakiotis T.; Giannakoulas G.; Efthimiadis G.K.; Argyropoulou P.; Parharidis G.E.; Bouros D. |
Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: A tissue Doppler echocardiographic study |
2008 |
| 110 |
Patoulias D.; Papadopoulos C.; Stavropoulos K.; Imprialos K.; Doumas M. |
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria |
2021 |
| 111 |
Stavropoulos K.; Papadopoulos C.; Koutsampasopoulos K.; Lales G.; Mitas C.; Doumas M. |
Mineralocorticoid receptor antagonists in primary aldosteronism |
2018 |
| 112 |
Papadopoulos C.E.; Karvounis H.I.; Gourasas I.T.; Parharidis G.E.; Louridas G.E. |
Evidence of ischemic preconditioning in patients experiencing first non-ST-segment elevation myocardial infarction (NSTEMI) |
2003 |
| 113 |
Papadopoulos C.E.; Matsiras S.; Vassilikos V. |
A rare case of lipomatous hypertrophy of the interventricular septum |
2016 |
| 114 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction |
2021 |
| 115 |
Papadopoulos C.E.; Pagourelias E.; Kallifatidis A.; Zioutas D.; Vassilikos V. |
Left ventricular outflow obstruction secondary to accessory mitral valve tissue in a patient with hypertrophic cardiomyopathy |
2015 |
| 116 |
Efthimiadis G.K.; Giannakoulas G.; Parcharidou D.G.; Karvounis H.I.; Mochlas S.T.; Styliadis I.H.; Papadopoulos C.E.; Kounatiadis P.; Pliakos C.I.; Parcharidis G.E.; Louridas G.E. |
Clinical significance of tissue Doppler imaging in patients with hypertrophic cardiomyopathy |
2007 |
| 117 |
Patoulias D.; Papadopoulos C.; Doumas M. |
The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients with Type 2 Diabetes |
2021 |
| 118 |
Pagourelias E.D.; Sotiriou P.; Papadopoulos C.E.; Cholongitas E.; Giouleme O.; Vassilikos V. |
Left Ventricular Myocardial Mechanics in Cirrhosis: A Speckle Tracking Echocardiographic Study |
2016 |
| 119 |
Papademetriou V.; Alataki S.; Stavropoulos K.; Papadopoulos C.; Bakogiannis K.; Tsioufis K. |
Pharmacological management of diabetic nephropathy |
2020 |
| 120 |
Papademetriou V.; Stavropoulos K.; Papadopoulos C.; Koutsampasopoulos K.; Dimitriadis K.; Tsioufis K. |
Role of pcsk9 inhibitors in high risk patients with dyslipidemia: Focus on familial hypercholesterolemia |
2018 |
| 121 |
Efthimiadis G.K.; Giannakoulas G.; Parcharidou D.G.; Ziakas A.G.; Papadopoulos C.E.; Karoulas T.; Pliakos C.; Parcharidis G. |
Subaortic and midventricular obstructive hypertrophic cardiomyopathy with extreme segmental hypertrophy |
2007 |
| 122 |
Patoulias D.; Papadopoulos C.; Toumpourleka M.; Bakatselos S.; Doumas M. |
Postdischarge antidiabetic treatment in patients with type 2 diabetes and acute coronary syndrome: Time for a change? |
2020 |
| 123 |
Loutradis C.; Papadopoulos C.E.; Sachpekidis V.; Ekart R.; Krunic B.; Karpetas A.; Bikos A.; Tsouchnikas I.; Mitsopoulos E.; Papagianni A.; Zoccali C.; Sarafidis P. |
Lung Ultrasound–Guided Dry Weight Assessment and Echocardiographic Measures in Hypertensive Hemodialysis Patients: A Randomized Controlled Study |
2020 |
| 124 |
Papadopoulos C.E.; Karvounis H.I.; Giannakoulas G.; Karamitsos T.D.; Efthimiadis G.K.; Parharidis G.E. |
Predictors of Left Ventricular Remodeling After Reperfused Acute Myocardial Infarction |
2007 |
| 125 |
Kassimis G.; Karamasis G.V.; Katsikis A.; Abramik J.; Kon-Togiannis N.; Didagelos M.; Petroglou D.; Papadopoulos C.E.; Poulimenos L.; Vassilikos V.; Kanonidis I.; Raina T.; Ziakas A. |
Should percutaneous coronary intervention be the standard treatment strategy for significant coronary artery disease in all octogenarians? |
2021 |
| 126 |
Patoulias D.; Katsimardou A.; Kalogirou M.-S.; Zografou I.; Toumpourleka M.; Imprialos K.; Stavropoulos K.; Stergiou I.; Papadopoulos C.; Doumas M. |
Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints |
2020 |
| 127 |
Papadopoulos C.E.; Karvounis H.I.; Parharidis G.E.; Louridas G.E. |
Preconditioning reduces QTc value in patients with first non-ST-segment elevation myocardial infarction (NSTEMI) |
2003 |
| 128 |
Papadopoulos C.; Kokkas B. |
ANP as a mediator of antihypertensive drug action |
1998 |
| 129 |
Giannakoulas G.; Karvounis H.; Koliakos G.; Damvopoulou T.; Karamitsos T.; Papadopoulos C.; Dalamanga E.; Hatzitolios A.; Parcharidis G.; Louridas G. |
Parathyroid hormone-related protein is reduced in severe chronic heart failure |
2006 |
| 130 |
Papadopoulos C.E.; Karvounis H.I.; Parharidis G.E.; Louridas G.E. |
Multiple episodes of ischemic preconditioning are not associated with loss of benefit: Preliminary clinical experience |
2005 |
| 131 |
Papadopoulos C.E.; Zioutas D.G.; Dalamaga E.G. |
Levosimendan and quality of life |
2010 |
| 132 |
Patoulias D.; Papadopoulos C.; Zografou I.; Doumas M. |
Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodium-glucose cotransporter-2 inhibitors? |
2020 |
| 133 |
Loutradis C.; Sarafidis P.A.; Ekart R.; Papadopoulos C.; Sachpekidis V.; Alexandrou M.E.; Papadopoulou D.; Efstratiadis G.; Papagianni A.; London G.; Zoccali C. |
The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial |
2019 |
| 134 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance? |
2020 |
| 135 |
Mouselimis D.; Tsarouchas A.S.; Pagourelias E.D.; Bakogiannis C.; Theofilogiannakos E.K.; Loutradis C.; Fragakis N.; Vassilikos V.P.; Papadopoulos C.E. |
Left atrial strain, intervendor variability, and atrial fibrillation recurrence after catheter ablation: A systematic review and meta-analysis |
2020 |
| 136 |
Koutsampasopoulos K.; Vogiatzis I.; Ziakas A.; Papadopoulos C.; Imprialos K.P.; Stavropoulos K.; Katsimardou A.; Patoulias D.; Bakogiannis C.; Vasilikos V.; Karagiannis A.; Doumas M. |
Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure |
2019 |
| 137 |
Patoulias D.; Papadopoulos C.; Katsimardou A.; Toumpourleka M.; Doumas M. |
Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions |
2020 |
| 138 |
Patoulias D.; Papadopoulos C.; Katsimardou A.; Kalogirou M.-S.; Doumas M. |
Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus |
2020 |
| 139 |
Patoulias D.; Papadopoulos C.; Katsimardou A.; Toumpourleka M.; Doumas M. |
Use of corticosteroids in SARS-CoV-2 infection: Foe, or can they become a friend? |
2020 |
| 140 |
Nikolaou M.; Chrysohoou C.; Georgilas T.A.; Giamouzis G.; Giannakoulas G.; Karavidas A.; Papadopoulos C.; Patsilinakos S.; Tziakas D.; Parissis J. |
Management of iron deficiency in chronic heart failure: Practical considerations for clinical use and future directions |
2019 |
| 141 |
Papadopoulos C.E.; Zioutas D.G.; Giannakoulas G.A.; Matsiras S.; Karamitsos T.D.; Karvounis H.I.; Geleris P.; Stiliadis I. |
Beneficial effect of ischemic preconditioning on post-infarction left ventricular remodeling and global left ventricular function |
2011 |
| 142 |
Loutradis C.; Sarafidis P.A.; Papadopoulos C.E.; Papagianni A.; Zoccali C. |
The Ebb and flow of echocardiographic cardiac function parameters in relationship to hemodialysis treatment in patients with ESRD |
2018 |
| 143 |
Tsarouchas A.; Mouselimis D.; Bakogiannis C.; Gkasdaris G.; Dimitriadis G.; Zioutas D.; Papadopoulos C.E. |
Spontaneous Epidural Hematoma of the Cervical Spine Following Thrombolysis in a Patient with STEMI-Two Medical Specialties Facing a Rare Dilemma |
2020 |
| 144 |
Styliadis I.H.; Papadopoulos C.E.; Gouzoumas N.I.; Giannakoulas G.; Karvounis H.I.; Karamouzis M.; Boufidon A.; Parharidis G.E. |
Similar pattern of diastolic function adaptation of both ventricles to programmed atrioventricular interval modification in patients with DDD pacing |
2006 |
| 145 |
Papadopoulos C.E.; Pitsiou G.; Karamitsos T.D.; Karvounis H.I.; Kontakiotis T.; Giannakoulas G.; Efthimiadis G.K.; Argyropoulou P.; Parharidis G.E.; Bouros D. |
Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: A tissue doppler ECG study (European Respiratory Journal (2008) 31, (701-706)) |
2008 |
| 146 |
Patoulias D.; Katsimardou A.; Papadopoulos C.; Doumas M. |
Diabetes mellitus and SARS‑CoV‑2‑related mortality: the impact of acute hyperglycemic crises and some further considerations |
2021 |
| 147 |
Papadopoulos C.E.; Pagourelias E.; Bakogiannis C.; Triantafyllou K.; Baltoumas K.; Kassimatis E.; Zioutas D.; Siskos D.; Tzikas S.; Fragakis N.; Papagianni A.; Vassilikos V. |
Left atrial deformation as a potent predictor for paroxysmal atrial fibrillation in patients with end-stage renal disease |
2018 |
| 148 |
Patoulias D.; Katsimardou A.; Toumpourleka M.; Kalogirou M.-S.; Papadopoulos C.; Doumas M. |
Meta-Analysis Assessing the Effects of Allopurinol on Left Ventricular Mass and Other Indices of Left Ventricular Remodeling as Evaluated by Cardiac Magnetic Resonance Imaging. |
2021 |
| 149 |
Karvounis H.I.; Nouskas I.G.; Farmakis T.M.; Vrogistinos K.M.; Papadopoulos C.E.; Zaglavara T.A.; Parharidis G.E.; Louridas G.E. |
Evaluation of a Doppler-Derived Index Combining Systolic and Diastolic Left Ventricular Function in Acute Myocardial Infarction |
2004 |
| 150 |
Papadopoulos C.E.; Fotoglidis A.; Pagourelias E.; Vassilikos V. |
A left atrial appendage phantom structure |
2016 |
| 151 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis |
2021 |
| 152 |
Patoulias D.; Papadopoulos C.; Katsimardou A.; Toumpourleka M.; Doumas M. |
Sodium–glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect? |
2020 |
| 153 |
Papadopoulos C.; Patoulias D.; Teperikidis E.; Mouselimis D.; Tsarouchas A.; Toumpourleka M.; Boulmpou A.; Bakogiannis C.; Doumas M.; Vassilikos V.P. |
Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review |
2020 |
| 154 |
Papadopoulos C.E.; Hatzimiltiadis S.M.; Gourassas I.T.; Karvounis H.I.; Koletsa T.D.; Karagiannopoulou G.K.; Louridas G.E. |
Cholesterol emboli syndrome |
2004 |
| 155 |
Gourassas J.; Albedd U.; Papadopoulos C.E.; Louridas G. |
Anomalous Origin of Right Radial Artery as a Cause of Radial Approach Failure of Coronary Angiography |
2003 |
| 156 |
Pagourelias E.D.; Papadopoulos C.E. |
Evaluation of myocardial function in pediatric patients with the transposition of great arteries after arterial switch operation |
2016 |
| 157 |
Karamitsos T.D.; Karvounis H.I.; Didangelos T.P.; Papadopoulos C.E.; Kachrimanidou M.K.; Selvanayagam J.B.; Parharidis G.E. |
Aortic elastic properties are related to left ventricular diastolic function in patients with type 1 diabetes mellitus |
2008 |
| 158 |
Kokkas B.; Papadopoulos C.; Kotoula M.; Kouyoumtzis A.; Myronidou M.; Missopoulou A.; Voulgaropoulos Ch.; Kanonidis I.; Sakadamis G.; Paradelis A. |
Clonidine and vasomotion physiology |
1998 |
| 159 |
Patoulias D.; Papadopoulos C.; Stavropoulos K.; Imprialos K.; Doumas M. |
Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients |
2020 |
| 160 |
Boulmpou A.; Kassimis G.; Zioutas D.; Meletidou M.; Mouselimis D.; Tsarouchas A.; Tzikas S.; Vassilikos V.; Kanonidis I.; Tsounos I.; Papadopoulos C.E. |
Spontaneous Coronary Artery Dissection (SCAD): Case Series and Mini Review |
2020 |
| 161 |
Karvounis H.I.; Papadopoulos C.E.; Ketikoglou D.G.; Zaglavara T.A.; Parharidis G.E.; Louridas G.E. |
Usefulness of low-dose dobutamine stress echocardiography for the evaluation of spontaneous recovery of stunned myocardium in patients with acute right ventricular infarction |
2005 |
| 162 |
Ketikoglou D.G.; Karvounis H.I.; Papadopoulos C.E.; Zaglavara T.A.; Efthimiadis G.K.; Parharidis G.E.; Louridas G.E. |
Echocardiographic evaluation of spontaneous recovery of right ventricular systolic and diastolic function in patients with acute right ventricular infarction associated with posterior wall left ventricular infarction |
2004 |
| 163 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target? |
2020 |
| 164 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Coronary artery disease, arterial stiffness, and myocardial work: What is the role of diabetes in this vicious circle? |
2021 |
| 165 |
Georgopoulou V.; Gouridou E.; Pyrpasopoulou A.; Kozanidou A.; Papadopoulos C.; Tzikas S.; Sidiropoulou M. |
An unusual cause of epigastric pain and diaphoresis |
2020 |
| 166 |
Pagourelias E.D.; Mirea O.; Duchenne J.; Unlu S.; Van Cleemput J.; Papadopoulos C.E.; Bogaert J.; Vassilikos V.P.; Voigt J.-U. |
Speckle tracking deformation imaging to detect regional fibrosis in hypertrophic cardiomyopathy: A comparison between 2D and 3D echo modalities |
2020 |
| 167 |
Stavropoulos K.; Imprialos K.P.; Katsiki N.; Petidis K.; Kamparoudis A.; Petras P.; Georgopoulou V.; Finitsis S.; Papadopoulos C.; Athyros V.G.; Doumas M.; Karagiannis A. |
Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone? |
2018 |
| 168 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials |
2021 |
| 169 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices? |
2021 |
| 170 |
Bakogiannis C.; Briasoulis A.; Mouselimis D.; Tsarouchas A.; Papageorgiou N.; Papadopoulos C.; Fragakis N.; Vassilikos V. |
Iron deficiency as therapeutic target in heart failure: a translational approach |
2020 |
| 171 |
Bakogiannis C.; Stavropoulos K.; Papadopoulos C.; Papademetriou V. |
The impact of various blood pressure measurements on cardiovascular outcomes |
2021 |
| 172 |
Papadopoulos C.E.; Giannakoulas G.A.; Karamitsos T.D.; Karvounis H.I.; Stiliadis I.; Parharidis G.E. |
Is Longitudinal Strain Associated with Left Ventricular Remodeling in Patients with Acute Myocardial Infarction? |
2008 |
| 173 |
Karvounis H.I.; Dalamaga E.G.; Papadopoulos C.E.; Karamitsos T.D.; Vassilikos V.; Paraskevaidis S.; Styliadis I.H.; Parharidis G.E.; Louridas G.E. |
Improved Papillary Muscle Function Attenuates Functional Mitral Regurgitation in Patients with Dilated Cardiomyopathy After Cardiac Resynchronization Therapy |
2006 |
| 174 |
Bakogiannis C.; Anastasios Tsarouchas, MD; Mouselimis D.; Lazaridis C.; Theofillogianakos E.K.; Billis A.; Tzikas S.; Fragakis N.; Bamidis P.D.; Papadopoulos C.E.; Vassilikos V.P. |
A patient-oriented app (ThessHF) to improve self-care quality in heart failure: From evidence-based design to pilot study |
2021 |
| 175 |
Patoulias D.; Toumpourleka M.; Papadopoulos C.; Doumas M. |
Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials |
2021 |
| 176 |
Patoulias D.; Papadopoulos C.; Stavropoulos K.; Zografou I.; Doumas M.; Karagiannis A. |
Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors |
2020 |
| 177 |
Karvounis H.I.; Papadopoulos C.E.; Zaglavara T.A.; Nouskas I.G.; Gemitzis K.D.; Parharidis G.E.; Louridas G.E. |
Evidence of left ventricular dysfunction in asymptomatic elderly patients with non-insulin-dependent diabetes mellitus |
2004 |
| 178 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Sclerostin and cardiovascular disease: Any prognostic implications? |
2021 |
| 179 |
Papadopoulos C.E.; Karvounis H.I.; Parharidis G.E. |
Is stress hyperglycaemia a prognostic marker of left ventricular remodelling after first anterior myocardial infarction? [5] |
2007 |
| 180 |
Patoulias D.; Papadopoulos C.; Doumas M. |
Sclerostin and cardiovascular disease: Any prognostic implications? |
2021 |
| 181 |
Papadopoulos C.E.; Zaglavara T.; Karvounis H.I.; Haaverstad R.; Parharidis G.E.; Louridas G.E.; Kenny A. |
QT dispersion is determined by the relative extent of normal, hibernating, and scarred myocardium in patients with chronic ischemic cardiomyopathy. A dobutamine stress echocardiography study before and after surgical revascularization |
2006 |
| 182 |
Patoulias D.; Papadopoulos C.; Katsimardou A.; Doumas M. |
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest |
2021 |
| 183 |
Kokkas B.; Papadopoulos C.; Mironidou M.; Kotoula M.; Kouyoumtzis A.; Kanonidis I.; Voulgaropoulos C.; Mirtsou V. |
Comparison of felodipine and nitroglycerin actions on vasomotion physiology |
1999 |
| 184 |
Kalinderi K.; Fragakis N.; Sotiriadou M.; Oriol D.-I.; Katritsis D.; Letsas K.; Korantzopoulos P.; Karamanolis A.; Pagourelias E.; Antoniadis A.P.; Dalampyras P.; Mavroudi M.; Kyriakou P.; Papadopoulos C.; Skeberis V.; Vassilikos V.; Fidani L. |
PRRX1 Rs3903239 polymorphism and atrial fibrillation in a Greek population |
2018 |
| 185 |
Patoulias D.; Katsimardou A.; Papadopoulos C.; Doumas M. |
Letter to the Editor: Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes |
2021 |
| 186 |
Gkantaifi A.; Papadopoulos C.; Spyropoulou D.; Toumpourleka M.; Iliadis G.; Tsoukalas N.; Kyrgias G.; Tolia M. |
Evaluation of the irradiated volume of the heart and cardiac substructures after left breast radiotherapy |
2020 |
| 187 |
Gkantaifi A.; Papadopoulos C.; Spyropoulou D.; Toumpourleka M.; Iliadis G.; Kardamakis D.; Nikolaou M.; Tsoukalas N.; Kyrgias G.; Tolia M. |
Breast radiotherapy and early adverse cardiac effects. The role of serum biomarkers and strain echocardiography |
2019 |
| 188 |
Toumpourleka M.; Patoulias D.; Katsimardou A.; Doumas M.; Papadopoulos C. |
Risk scores and prediction models in chronic heart failure: A comprehensive review |
2021 |
| 189 |
Karamitsos T.D.; Karvounis H.I.; Dalamanga E.G.; Papadopoulos C.E.; Didangellos T.P.; Karamitsos D.T.; Parharidis G.E.; Louridas G.E. |
Early diastolic impairment of diabetic heart: The significance of right ventricle |
2007 |
| 190 |
Efthimiadis G.K.; Parharidis G.E.; Karvounis H.I.; Papadopoulos C.E.; Gemitzis K.D.; Styliadis I.H.; Karoulas T.N.; Louridas G.E. |
Left ventricular doppler characteristics in first-degree relatives of patients with hypertrophic cardiomyopathy |
2005 |
| 191 |
Karamitsos T.D.; Karvounis H.I.; Didangellos T.P.; Papadopoulos C.E.; Dalamanga E.G.; Karamitsos D.T.; Parharidis G.E.; Louridas G.E. |
Usefulness of colour tissue Doppler imaging in assessing aortic elastic properties in Type 1 diabetic patients |
2006 |
| 192 |
Gourassas J.T.; Papadopoulos C.E.; Louridas G.E. |
Percutaneous Ulnar Artery Approach for Coronary Angioplasty |
2004 |
| 193 |
Patoulias D.; Papadopoulos C.; Kalogirou M.-S.; Katsimardou A.; Toumpourleka M.; Doumas M. |
Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction |
2020 |
| 194 |
Patoulias D.; Katsimardou A.; Toumpourleka M.; Papadopoulos C.; Doumas M. |
Time to assess the effects of sodium–glucose co-transporter-2 inhibitors on the ‘forgotten’ right ventricle? |
2020 |
| 195 |
Pitsiou G.; Papadopoulos C.E.; Karvounis H.I.; Karamitsos T.D.; Giannakoulas G.; Efthimiadis G.; Kontakiotis T.; Argiropoulou P.; Parharidis G.E. |
Utility of tissue doppler imaging in predicting outcome in patients with idiopathic pulmonary fibrosis |
2007 |
